CLOs on the Move

Alcami

www.alcami.com

 
Alcami is a contract development and manufacturing organization headquartered in North Carolina with over 40 years of experience advancing products through every stage of the development lifecycle. Alcami serves pharmaceutical and biotech companies of all sizes for small molecules and biologics, providing customizable and innovative solutions for analytical development, clinical to commercial sterile and oral solid dose drug product manufacturing, packaging, microbiology, cGMP biostorage, environmental monitoring, and pharmaceutical support services. Alcami`s private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.alcami.com
  • 2320 Scientific Park Drive
    Wilmington, NC USA 28405
  • Phone: 910.254.7000

Executives

Name Title Contact Details

Similar Companies

Quark Pharmaceuticals

Quark Pharmaceuticals is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Drugs

United Drugs is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Westminster Pharmaceuticals

Westminster Pharmaceuticals is dedicated to improving patient outcomes and reducing the cost of healthcare.

Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications, and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions.

Myonexustx

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.